67 - 1 N Engl J Med 1996 May 30;334(22:1435-9 Famotidine...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Sheet1 Page 1 1. N Engl J Med. 1996 May 30 334(22):1435-9. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI. Department of Gastroenterology, Glasgow Royal Infirmary, Scotland. Comment in: ACP J Club. 1996 Nov-Dec 125(3):79. N Engl J Med. 1996 Oct 24 335(17):1322 BACKGROUND. Acid suppression with famotidine, a histamine H2-receptor antagonist, provides protection against gastric injury in normal subjects receiving short courses of aspirin or naproxen. The efficacy of famotidine in preventing peptic ulcers in patients receiving long-term therapy with nonsteroidal antiinflammatory drugs (NSAIDs) is not known. METHODS. We studied the efficacy of two doses of famotidine (20 mg and 40 mg, each given orally twice daily), as compared with placebo, in preventing peptic ulcers in 285 patients without peptic ulcers who
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 01/10/2010 for the course NSA 1010 taught by Professor Ahobaishi during the Spring '09 term at ND State.

Page1 / 2

67 - 1 N Engl J Med 1996 May 30;334(22:1435-9 Famotidine...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online